Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
SkinBioTherapeutics ( (GB:SBTX) ) just unveiled an update.
SkinBioTherapeutics announced the departure of Simon Hewitson, the Executive Director and Chief Operating Officer, due to personal reasons. His responsibilities will be temporarily managed by CEO Stuart Ashman and Group Finance Director Emily Bertram while the company seeks a successor. This change in leadership may impact the company’s operations and strategic direction, particularly in its partnerships and acquisitions in the skin health sector.
The most recent analyst rating on (GB:SBTX) stock is a Sell with a £16.00 price target. To see the full list of analyst forecasts on SkinBioTherapeutics stock, see the GB:SBTX Stock Forecast page.
Spark’s Take on GB:SBTX Stock
According to Spark, TipRanks’ AI Analyst, GB:SBTX is a Underperform.
SkinBioTherapeutics faces significant financial challenges with ongoing losses and cash burn, which heavily influence its stock score. While technical indicators show bearish trends, recent positive corporate events and strategic moves offer potential future benefits. However, until these translate into improved financial performance, the stock’s score remains low.
To see Spark’s full report on GB:SBTX stock, click here.
More about SkinBioTherapeutics
SkinBioTherapeutics is a life science company focused on skin health, utilizing its proprietary platform technology, SkinBiotix®, developed by the University of Manchester’s dermatology team. The company targets the skin healthcare market through five pillars, with a focus on cosmetic skincare and food supplements, including partnerships and acquisitions to expand its reach and capabilities.
Average Trading Volume: 723,490
Technical Sentiment Signal: Sell
Current Market Cap: £37.52M
For detailed information about SBTX stock, go to TipRanks’ Stock Analysis page.